Bli medlem
Bli medlem

Du är här

2019-05-09

2cureX: CORRECTION: 2cureX publishes interim report for the first quarter of 2019

This is a correction of the announcement from 08:30 08.05.2019 CEST.
Reason for the correction: Delårsrapport bilagts in full length.

2cureX AB ("2cureX") hereby publishes the interim report for the first
quarter of 2019. The interim report is available as an attached
document as well as on the company's website (www.2curex.com). Below
follows a short summary of the report.

CEO Ole Thastrup comments

"We have started 2019 with great momentum and during the first three
months we have been able to achieve several value-driving activities.
We have among other things strengthened the organization through the
recruitment of a CFO, presented successful interim results from the
ongoing validation study in colorectal cancer and in addition
expanded the business to be operational in preventive cancer
medicine. In parallel with this, we have continued our preparatory
activities for the market launch of IndiTreat®. It feels very
exciting to have accomplished the above activities and I look forward
to seeing the continued development during the year."

First quarter (2019-01-01 until 2019-03-31) - the group

· Net turnover for the period was 0 KSEK (0 KSEK).
· The result before tax was -1,913 KSEK (-2,944 KSEK).
· The result per share* was -0.15 SEK (-0.28 SEK).
· The solidity** was 57 % (53 %).
· The cash and bank were 17,167 KSEK (30,675 KSEK).

*Result per share: The result of the period divided by the average
number of shares. Average number of shares for the first quarter
2019: 10 350 000 shares. Total number of shares in 2cureX AB on March
31st, 2019: 10 350 000 shares.

**Solidity: Equity divided by total capital.

Significant events during the first quarter 2019

· In mid-January 2019, 2cureX strengthens the organisation by
recruiting Carit J. Andersen as CFO for the Company.

· At the end of February 2019, 2cureX announced that the Company's
first clinical trial, where IndiTreat® guides treatment, has achieved
both the primary and secondary endpoints of an interim analysis. Of
eight patients treated according to IndiTreat® test results, five
patients experienced progression-free survival (PFS) eight weeks
after initiation of treatment.

· In mid-March 2019, 2cureX expands its activities to preventative
cancer medicine by launching, together with the University Hospital
Bispebjerg (Copenhagen, Denmark), a feasibility study to use the
IndiTreat® test in order to identify existing or new drugs that can
prevent cancer precursors (adenoma) from developing. to fully
developed colorectal cancer.

· In mid-March 2019, 2cureX publishes a notice for an extraordinary
general meeting. Full notice with proposed decisions is available on
the Company's website (www.2curex.com).

· At the end of March 2019, 2cureX receives a Notice of Allowance
from the US Patent Office regarding the patent "Identifying compounds
modifying a cellular phenotype", which has previously been approved
in the European market. The US patent will be valid until early July
2035.

Significant events after the period

· At the beginning of April 2019, 2cureX holds an extraordinary
general meeting. Communique with a summary of decisions made is
available on the Company's website (www.2curex.com).

· In early April 2019, 2cureX announces a commercial cooperation
with Gibson Oncology LLC, USA. 2cureX will use its IndiTreat®
technology to stratify colorectal cancer (CRC) patients for their
sensitivity to the anti-cancer drug LMP400.

· 2cureX announces that the Board of Directors, with the support of
authorisation from the extraordinary general meeting on April 2nd,
2019, has decided to conduct a rights issue of shares that can
provide the company a maximum of approximately SEK 24.7 million
before issue costs.

Certified Adviser

Sedermera Fondkommission
E-mail: ca@sedermera.se
Phone: +46 40 615 14 15

For more information about 2cureX:

Ole Thastrup, CEO
E-mail: ot@2curex.com
Phone: +45 221153 99
URL: www.2curex.com

This information is information that 2cureX AB is obliged to make
public pursuant to the EU Market Abuse Regulation. The information
was submitted for publication, through the agency of the contact
person set out above, on May 8th, 2019.

About 2cureX

2cureX has developed a test called IndiTreat® (Individual Treatment
Design), which is a patented method for selecting the right drug for
the right patient. IndiTreat® establishes thousands of 3D
micro-tumours that are functionally similar to the patient's tumour.
From a large panel of approved cancer treatments IndiTreat® selects
the best treatment for the individual patient. IndiTreat® is expected
to become a standard tool in the treatment design for cancer
patients.

IndiTreat® is currently being clinically validated in colorectal
cancer, ovarian cancer, pancreatic cancer and preventive cancer
medicine. The clinical studies are conducted at major cancer
hospitals in Denmark, Germany and United Kingdom.

The company is listed at the Nasdaq First North stock exchange in
Stockholm (symbol "2CUREX").

-----------------------------------------------------------
https://news.cision.com/se/2curex/r/correction--2curex-publishes-interim...
https://mb.cision.com/Main/16432/2807673/1040511.pdf
https://mb.cision.com/Public/16432/2807673/829838143e801555.pdf

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.